Seagen Inc. (NASDAQ:SGEN) Shares Acquired by Fulton Bank N.A.


Share on StockTwits

Fulton Bank N.A. lifted its position in shares of Seagen Inc. (NASDAQ:SGEN) by 2.8% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 6,721 shares of the biotechnology company’s stock after buying an additional 186 shares during the period. Fulton Bank N.A.’s holdings in Seagen were worth $934,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Regent Peak Wealth Advisors LLC acquired a new stake in shares of Seagen during the fourth quarter worth $30,000. Capital Advisory Group Advisory Services LLC acquired a new position in shares of Seagen in the 3rd quarter valued at $33,000. Endurance Wealth Management Inc. boosted its holdings in shares of Seagen by 100.0% in the 4th quarter. Endurance Wealth Management Inc. now owns 200 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 100 shares during the last quarter. Glassman Wealth Services purchased a new stake in shares of Seagen during the 4th quarter valued at $36,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Seagen by 765.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 225 shares of the biotechnology company’s stock worth $39,000 after buying an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 87.15% of the company’s stock.

In related news, EVP Jean I. Liu sold 5,000 shares of the company’s stock in a transaction dated Friday, January 15th. The shares were sold at an average price of $180.00, for a total value of $900,000.00. Following the completion of the sale, the executive vice president now owns 65,266 shares of the company’s stock, valued at $11,747,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Clay B. Siegall sold 29,353 shares of the company’s stock in a transaction dated Thursday, February 4th. The stock was sold at an average price of $165.57, for a total transaction of $4,859,976.21. The disclosure for this sale can be found here. Insiders sold 75,706 shares of company stock worth $11,876,522 in the last 90 days. 31.10% of the stock is owned by company insiders.

A number of brokerages have weighed in on SGEN. Credit Suisse Group initiated coverage on shares of Seagen in a research report on Tuesday, March 30th. They set a “neutral” rating and a $145.00 price target on the stock. Royal Bank of Canada dropped their price objective on shares of Seagen from $186.00 to $169.00 and set a “sector perform” rating on the stock in a research note on Tuesday, February 16th. William Blair restated an “outperform” rating on shares of Seagen in a research note on Tuesday, February 9th. SVB Leerink cut their price objective on shares of Seagen from $200.00 to $192.00 and set an “outperform” rating on the stock in a report on Friday, February 12th. Finally, Piper Sandler lowered their target price on Seagen from $175.00 to $170.00 and set a “neutral” rating for the company in a research note on Friday, February 12th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Seagen has an average rating of “Buy” and a consensus target price of $181.80.

Shares of NASDAQ SGEN traded up $2.61 during mid-day trading on Thursday, hitting $147.24. The company had a trading volume of 462 shares, compared to its average volume of 1,188,354. The stock has a market cap of $26.67 billion, a price-to-earnings ratio of 56.94 and a beta of 1.11. The firm’s 50 day simple moving average is $148.56 and its two-hundred day simple moving average is $174.09. Seagen Inc. has a 12 month low of $117.91 and a 12 month high of $213.94.

Seagen (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, February 11th. The biotechnology company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.81 by $0.09. Seagen had a net margin of 25.34% and a return on equity of 20.46%. The business had revenue of $601.29 million during the quarter, compared to analyst estimates of $583.58 million. During the same quarter in the prior year, the firm earned $0.14 earnings per share. Equities analysts anticipate that Seagen Inc. will post 3.19 earnings per share for the current year.

About Seagen

Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Featured Article: SEC Filing

Institutional Ownership by Quarter for Seagen (NASDAQ:SGEN)

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.